Spots Global Cancer Trial Database for advanced renal cell carcinoma
Every month we try and update this database with for advanced renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent | NCT00836745 | Renal Cell Carc... | Non Interventio... | 18 Years - 75 Years | Pfizer | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC | NCT02143492 | Kidney Cancer Renal Cell Carc... Advanced Renal ... | 18 Years - | Argos Therapeutics | ||
| Pazopanib in Second-line Therapy in Renal Cell Carcinoma | NCT01577784 | Metastatic Rena... | Pazopanib | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | NCT01076010 | Advanced Renal ... | Tivozanib Sorafenib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | NCT00853372 | Advanced Renal ... | Sunitinib Trebananib | 18 Years - | Amgen | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | NCT01664182 | Advanced Renal ... Advanced Sarcom... Stage III Renal... Stage IV Renal ... | Bevacizumab Pazopanib Hydro... Sorafenib Tosyl... Sunitinib Malat... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | NCT05262413 | Advanced Renal ... | QL1706 Plus Len... | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | NCT00425035 | Advanced Renal ... | Panitumumab (AB... | - | Amgen | |
| A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer | NCT01114230 | Renal Cell Carc... Pharmacokinetic... | AGS-16M8F | 18 Years - | Astellas Pharma Inc | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | NCT04514484 | Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK | NCT03696407 | Advanced Renal ... | 18 Years - | Ipsen | ||
| A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer | NCT01114230 | Renal Cell Carc... Pharmacokinetic... | AGS-16M8F | 18 Years - | Astellas Pharma Inc | |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | NCT05092373 | Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... | Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of ST-1898 in Advanced Renal Cell Carcinoma | NCT06127238 | Advanced Renal ... | ST-1898 tablets | 18 Years - | Beijing Scitech-Mq Pharmaceuticals Limited | |
| Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | NCT00425204 | Colorectal Canc... Non-Small Cell ... Prostate Cancer Solid Tumors Advanced Renal ... | Panitumumab (AB... | 18 Years - | Amgen | |
| Study of ST-1898 in Advanced Renal Cell Carcinoma | NCT06127238 | Advanced Renal ... | ST-1898 tablets | 18 Years - | Beijing Scitech-Mq Pharmaceuticals Limited | |
| Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | NCT02156895 | Advanced Renal ... | Axitinib | 18 Years - | Pfizer | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | NCT03707574 | Advanced Malign... Advanced Melano... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage IIIA Colo... Stage IIIA Lung... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Colo... Stage IIIB Lung... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Colo... Stage IIIC Lung... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVA Color... Stage IVA Lung ... Stage IVA Ovari... Stage IVA Prost... Stage IVB Color... Stage IVB Lung ... Stage IVB Ovari... Stage IVB Prost... Stage IVC Color... | Biospecimen Col... | 18 Years - | National Cancer Institute (NCI) | |
| Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | NCT00044564 | Carcinoma, Rena... | Bay 59-8862 | 18 Years - | Bayer | |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy | NCT04941365 | Metastatic Mela... Metastatic Brea... Advanced Renal ... Squamous Cell C... Non-small Cell ... Healthy | single arm | 18 Years - 90 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | NCT01582672 | Advanced Renal ... Renal Cell Carc... Metastatic Rena... | Standard Treatm... AGS-003 | 18 Years - | Argos Therapeutics | |
| Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | NCT02231749 | Advanced Renal ... Metastatic Rena... | Nivolumab Ipilimumab Sunitinib | 18 Years - | Bristol-Myers Squibb | |
| Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | NCT00142415 | Metastatic Rena... | 111-In-DOTA-cG2... 177-Lu-DOTA-cG2... | 18 Years - | Ludwig Institute for Cancer Research | |
| AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | NCT00853372 | Advanced Renal ... | Sunitinib Trebananib | 18 Years - | Amgen | |
| Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | NCT02231749 | Advanced Renal ... Metastatic Rena... | Nivolumab Ipilimumab Sunitinib | 18 Years - | Bristol-Myers Squibb | |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma | NCT04969354 | Immunotherapy | CAR-T cell immu... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | NCT00467025 | Advanced Renal ... | AMG 386 Sorafenib AMG 386 placebo... | 18 Years - | Amgen | |
| Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | NCT00142415 | Metastatic Rena... | 111-In-DOTA-cG2... 177-Lu-DOTA-cG2... | 18 Years - | Ludwig Institute for Cancer Research | |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | NCT06265285 | Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc... | Home Health Enc... Nivolumab Patient Monitor... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Study of ST-1898 in Advanced Renal Cell Carcinoma | NCT06127238 | Advanced Renal ... | ST-1898 tablets | 18 Years - | Beijing Scitech-Mq Pharmaceuticals Limited | |
| IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients | NCT05641545 | Advanced Renal ... | IVAC | 18 Years - | SLK Kliniken Heilbronn GmbH | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | NCT02156895 | Advanced Renal ... | Axitinib | 18 Years - | Pfizer | |
| Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | NCT00425204 | Colorectal Canc... Non-Small Cell ... Prostate Cancer Solid Tumors Advanced Renal ... | Panitumumab (AB... | 18 Years - | Amgen | |
| Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | NCT00425204 | Colorectal Canc... Non-Small Cell ... Prostate Cancer Solid Tumors Advanced Renal ... | Panitumumab (AB... | 18 Years - | Amgen | |
| Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma | NCT03229083 | Advanced Renal ... | Carevive softwa... | 18 Years - | University of Rochester | |
| Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | NCT00486538 | Advanced Renal ... | ABT-869 | 18 Years - | AbbVie | |
| Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | NCT00494091 | Advanced Renal ... | Temsirolimus (C... Temsirolimus (C... | 20 Years - | Pfizer | |
| Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma | NCT03229083 | Advanced Renal ... | Carevive softwa... | 18 Years - | University of Rochester | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | NCT04902040 | Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ... | Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | NCT03829111 | Advanced Renal ... Clear Cell Rena... Metastatic Rena... Stage III Renal... Stage IV Renal ... Unresectable Re... | Clostridium but... Ipilimumab Nivolumab | 18 Years - | City of Hope Medical Center | |
| Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | NCT01513187 | Advanced Renal ... | Pazopanib + int... | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma | NCT04969354 | Immunotherapy | CAR-T cell immu... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | NCT02002312 | Metastatic Clea... | Lu-177-DOTA-gir... | 18 Years - | Radboud University Medical Center | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | NCT04902040 | Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ... | Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | NCT05868174 | Solid Tumor, Ad... Advanced Solid ... Advanced Renal ... | 89Zr-TLX250 177Lu-TLX250 an... | 18 Years - | Telix Pharmaceuticals (Innovations) Pty Limited | |
| Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma | NCT00065468 | Carcinoma, Rena... Kidney Neoplasm... | Interferon Alfa CCI-779 Interferon Alfa... | 18 Years - | Pfizer | |
| Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | NCT05928806 | Advanced Renal ... | Botensilimab Balstilimab Ipilimumab Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK | NCT05394493 | Advanced Renal ... | avelumab axitinib | 18 Years - | Pfizer | |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | NCT01297244 | Renal Cell Carc... | Tivozanib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | NCT00486538 | Advanced Renal ... | ABT-869 | 18 Years - | AbbVie | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Dendritic Cell Based Therapy of Renal Cell Carcinoma | NCT00197860 | Advanced Renal ... | tumor antigen l... | 18 Years - | Herlev Hospital | |
| Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | NCT01727336 | Advanced Renal ... | Dalantercept an... Placebo and axi... | 18 Years - | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | |
| AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | NCT00853372 | Advanced Renal ... | Sunitinib Trebananib | 18 Years - | Amgen | |
| Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | NCT04203901 | Advanced Renal ... | CMN-001 Nivolumab+Ipili... Lenvatinib+Ever... | 18 Years - | CoImmune | |
| A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | NCT03339219 | Advanced Renal ... | Cabozantinib | 20 Years - | Takeda | |
| Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar | NCT00895674 | Carcinoma, Rena... Carcinoma, Rena... | Nexavar (Sorafe... | 18 Years - | Bayer | |
| Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | NCT00486538 | Advanced Renal ... | ABT-869 | 18 Years - | AbbVie | |
| A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | NCT05262413 | Advanced Renal ... | QL1706 Plus Len... | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | NCT03829111 | Advanced Renal ... Clear Cell Rena... Metastatic Rena... Stage III Renal... Stage IV Renal ... Unresectable Re... | Clostridium but... Ipilimumab Nivolumab | 18 Years - | City of Hope Medical Center | |
| Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | NCT00425035 | Advanced Renal ... | Panitumumab (AB... | - | Amgen | |
| Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. | NCT03647878 | Advanced Renal ... Metastatic Rena... | 18 Years - | Ipsen | ||
| Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | NCT01582672 | Advanced Renal ... Renal Cell Carc... Metastatic Rena... | Standard Treatm... AGS-003 | 18 Years - | Argos Therapeutics | |
| A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma | NCT01030783 | Advanced Renal ... | tivozanib (AV-9... Sorafenib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | NCT01297244 | Renal Cell Carc... | Tivozanib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | NCT00467025 | Advanced Renal ... | AMG 386 Sorafenib AMG 386 placebo... | 18 Years - | Amgen | |
| Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC | NCT02143492 | Kidney Cancer Renal Cell Carc... Advanced Renal ... | 18 Years - | Argos Therapeutics | ||
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | NCT06265285 | Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc... | Home Health Enc... Nivolumab Patient Monitor... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | NCT04071223 | Advanced Renal ... Chromophobe Ren... Clear Cell Rena... Collecting Duct... Kidney Medullar... Metastatic Mali... Papillary Renal... Stage IV Renal ... Unclassified Re... | Cabozantinib S-... Quality-of-Life... Questionnaire A... Radium Ra 223 D... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | NCT03339219 | Advanced Renal ... | Cabozantinib | 20 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
